Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Colorectal Biologic Trials

Virginia

Colorectal cancer biologic therapy trials in Virginia

10 colorectal cancer biologic therapy studies are recruiting participants at sites in 15 cities across Virginia as of November 18, 2026, according to ClinicalTrials.gov.

Call (888) 413-6546
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Browse Virginia by city

Cities with the most studies recruiting right now.

Every Virginia city with a recruiting study

Fairfax (6), Richmond (5), Arlington (3), Charlottesville (2), Roanoke (2), Blacksburg (1), Low Moor (1), Manassas (1), Mechanicsville (1), Midlothian (1), Petersburg (1), Reston (1), Salem (1), Woodbridge (1), Wytheville (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Recently updated studies in Virginia

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    SOTIO Biotech a.s.
    Recruiting in
    Fairfax
    Registry record
    NCT07693751 · updated
  2. A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Charlottesville · Fairfax
    Registry record
    NCT06997497 · updated
  3. Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Charlottesville · Richmond
    Registry record
    NCT06102902 · updated
  4. A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Recruiting in
    Arlington · Fairfax · Richmond
    Registry record
    NCT06662786 · updated
  5. A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Recruiting in
    Arlington · Richmond
    Registry record
    NCT06750094 · updated
  6. A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Roanoke
    Registry record
    NCT06428409 · updated
  7. Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Recruiting in
    Arlington · Blacksburg · Fairfax · and 11 more U.S. locations
    Registry record
    NCT07222800 · updated
  8. A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Cartography Biosciences
    Recruiting in
    Fairfax
    Registry record
    NCT07321106 · updated
  9. Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    GlaxoSmithKline
    Recruiting in
    Richmond
    Registry record
    NCT05855200 · updated
  10. A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    GV20 Therapeutics
    Recruiting in
    Fairfax
    Registry record
    NCT05669430 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Virginia on ClinicalTrials.gov.

Ask about studies in Virginia

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.

Colorectal Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 413-6546

or send a short form

How should we reach you?

Call